Compare Global X Copper Miners ETF (COPX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Novo Nordisk A/S — how do they compare? Global X Copper Miners ETF trades at $84.76 (market cap $7.10B), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 23.3× Global X Copper Miners ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Novo Nordisk A/S for 116 Days on average.
| COPX | NVO | |
|---|---|---|
Market Cap | $7.10B | $165.31B |
Volume | 2,871,128 | 11,432,838 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $63.98 |
52-Week Low | $57.43 | $35.29 |
Typical Hold Time | 50 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $83.58, down 3.13% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces pressure despite positive copper market fundamentals, with copper prices reaching all-time highs near $6.85 per pound. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though mining equities have underperformed the underlying metal.
The copper shortage narrative supports long-term growth potential, but near-term headwinds include global surplus projections and Federal Reserve policy concerns. COPX offers leveraged exposure to copper prices, with analysts divided between buying dips and cautious holding patterns given valuation concerns and mining operational challenges.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
